No GLP-1 permission should be inferred from it. The HHS document’s Appendix A lists BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500; it does not list semaglutide or tirzepatide. The policy concerns specified section 503A peptide compounding and imposes conditions. HHS policy. (hhs.gov)
The October 30 Federal Register notice describes the document as draft/interim, states that it creates no rights and is not binding, and allows comments for two weeks after publication. Do not describe it as FDA approval or a final statutory safe harbour. Official notice. (govinfo.gov)
Buyer action: keep a proposed peptide service expansion in a separate legal, clinical and procurement review. A supplier’s broader wellness catalogue is not evidence supporting its GLP-1 offering.
Sources cited on this page
- hhs.gov · Source 1 ↗https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy.pdf
- govinfo.gov · Source 2 ↗https://www.govinfo.gov/content/pkg/FR-2026-10-30/html/2026-22192.htm